Impact of a Better Persistence with Antihypertensive Agents on Ischemic Stroke Outcomes for Secondary Prevention

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Xu, Jie ^a   Zhao, Xingquan ^a   Wang, Yilong ^a   Wang, Chunxue ^a   Liu, Liping ^a   Sun, Baoying ^b   Wang, Anxin ^a   Wang, Yongjun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGED; ARTICLE; BRAIN ISCHEMIA; CHINA; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RECURRENT DISEASE; REGISTER; RISK REDUCTION; SECONDARY PREVENTION; SELF REPORT; VASCULAR DISEASE;

AGED; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; SECONDARY PREVENTION; STROKE;

EID: 84878955283     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065233     Document Type: Article

References (23)

1. PATS Collaborating Group (1995) Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl) 108: 710-717.
2. Heart Outcomes Prevention Evaluation Study Investigators, (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259.
3. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, et al. (2005) Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36: 1218-1226.
4. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, et al. (2008) Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359: 1225-1237.
5. Group. PC (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033-1041.
6. Rashid P, Leonardi-Bee J, Bath P, (2003) Blood pressure reduction and secondary prevention of stroke and other vascular events. Stroke 34: 2741-2748.
7. Liu L, Wang Z, Gong L, Zhang Y, Thijs L, et al. (2009) Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res 32: 1032-1040.
8. Ho PM, Bryson CL, Rumsfeld JS, (2009) Medication adherence: its importance in cardiovascular outcomes. Circulation 119: 3028-3035.
9. Osterberg L, Blaschke T, (2005) Adherence to medication. N Engl J Med 353: 487-497.
10. Wang Y, Cui L, Ji X, Dong Q, Zeng J, et al. (2011) The China National Stroke Registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke 6: 355-361.
11. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke 20: 1407-1431.
12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252.
13. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, et al. (1989) Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20: 864-870.
14. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C, (1991) Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337: 1521-1526.
15. Ovbiagele B, Campbell S, Faiz A, Chambless LE, (2009) Relationship between Non-Specific Prescription Pill Adherence and Ischemic Stroke Outcomes. Cerebrovascular Diseases 29: 146-153.
16. Kettani FZ, Dragomir A, Cote R, Roy L, Berard A, et al. (2009) Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 40: 213-220.
17. Bushnell C, Olson D, Zhao X, Pan W, Zimmer L, et al. (2011) Secondary preventive medication persistence and adherence 1 year after stroke. Neurology 77: 1182-1190.
18. Muntner P, Halanych JH, Reynolds K, Durant R, Vupputuri S, et al. (2011) Low medication adherence and the incidence of stroke symptoms among individuals with hypertension: the REGARDS study. J Clin Hypertens (Greenwich) 13: 479-486.
19. Gehi AK, Ali S, Na B, Whooley MA, (2007) Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Archives of internal medicine 167: 1798.
20. Colivicchi F, Bassi A, Santini M, Caltagirone C, (2007) Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 38: 2652-2657.
21. Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, et al. (1980) Can simple clinical measurements detect patient noncompliance? Hypertension 2: 757-764.
22. Walsh JC, Mandalia S, Gazzard BG, (2002) Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. Aids 16: 269-277.
23. Graves JW, White CL, Szychowski JM, Pergola PE, Benavente OR, et al. (2012) Predictors of lowering SBP to assigned targets at 12 months in the Secondary Prevention of Small Subcortical Strokes study. J Hypertens 30: 1233-1240.